


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
ENTERING INTO THE COOPERATIVE AGREEMENT IN RELATION TO
COMBINATION THERAPIES

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that CTTQ-Akeso (Shanghai) Biomed. Tech. Co., Ltd. (正大天晴康方(上海)生物醫藥科技有限公司) (“**CTTQ-Akeso**”), an associate of the Group, entered into the cooperative agreement with Xuanzhu Biopharmaceutical Co., Ltd. (軒竹生物科技股份有限公司) (“**Xuanzhu Biopharm**”) in relation to combination therapies, pursuant to which, both parties agreed to jointly carry out exploration and experiments on the PD-1 monoclonal antibody Penpulimab of CTTQ-Akeso and the AXL inhibitor of Xuanzhu Biopharm, with an aim of developing their application of combination therapies for solid tumors.

By taking full advantage of the expertise of Akeso in immunotherapies for tumors by macromolecules and that of Xuanzhu Biopharm in targeted therapies for tumors by small molecules, this cooperation will explore the application of combination immunotherapies in fields such as non-small cell lung cancer to benefit more cancer patients.

ABOUT XUANZHU BIOPHARM

Xuanzhu Biopharm is an innovative biopharmaceutical company rooted in the PRC with a global perspective and a focus on fields such as tumors, digestion and metabolism. It has a domestically first-class platform for independent research and development of innovative small molecule and macromolecule drugs, with a product pipeline covering directions including small molecules, monoclonal antibodies, bispecific antibodies, fusion proteins, and ADC (antibody drug conjugates).

ABOUT AXL INHIBITOR

This product is a highly selective, oral, small molecule AXL inhibitor. As a member of the TAM (Tyro3, AXL and Mer) family of tyrosine protein kinases, AXL, along with its ligand GAS6, is highly expressed and activated in many malignant tumors. The GAS6-AXL signaling pathway, as one of the crucial signaling pathways promoting tumor growth and metastasis, tumor immune escape and drug resistance, is considered to be a new target for cancer treatment. The product is currently in the phase I/II clinical studies in North America.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 21 April 2022

As at the date of this announcement, the Board of the Company comprises nine executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Li Yi, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.